



## EFFECTS OF DIABETES ON CARDIAC CONTRACTILE PROTEINS AND REVERSAL WITH INSULIN

Adnan Ali<sup>1</sup>, Sumaiya Muhammad Iqbal Memon<sup>2</sup>, Badar Munir<sup>3\*</sup>, Maeesa Wadood<sup>4</sup>,  
Muhammad Rizwan<sup>5</sup>, Shahid Pervez Shaikh<sup>6</sup>

<sup>1</sup>Assistant Professor of Medicine and Endocrinologist, Central Park Medical College & Teaching Hospital, Lahore Pakistan

<sup>2</sup>Senior Registrar Emergency Department, NICVD, Karachi Pakistan

<sup>3\*</sup>Medical Officer, Saadat Medical Complex, Narowal, Pakistan

<sup>4</sup>Associate Professor, Department of Pathology, Baqai Medical University, Karachi Pakistan

<sup>5</sup>Associate Professor, Baqai Institute of Hematology, Baqai Medical University, Karachi Pakistan

<sup>6</sup>Associate Professor Anatomy, Baqai Medical University, Karachi, Pakistan

\*Corresponding Author :- Badar Munir

Email: badar.munir.528@gmail.com

### ABSTRACT

**Introduction:** Diabetes mellitus poses a serious threat to global health due to its well-known devastating effects on the cardiovascular system. A crucial part of preserving circulatory homeostasis is the contractile activity of the heart, which is controlled by cardiac contractile proteins. However, research is still ongoing into the processes by which diabetes alters these proteins and the possibility of their reversal with insulin therapy.

**Methods:** In the medicine department of Central Park Medical College & Teaching Hospital, Lahore Pakistan, a 9-month prospective longitudinal research was conducted. Glycemic control, cardiac contractile proteins, and heart function were carefully examined at baseline and nine months in a group of 150 adult individuals. For comparison analysis, participants were divided into diabetes groups with and without insulin therapy as well as a control group.

**Results:** Both diabetic groups showed improved glycemic control, with HbA1c levels in the diabetic insulin group (DIG) falling from 8.3% to 7.9%. The Diabetic Group's (DG) fasting blood glucose levels dropped from 166.2 mg/dL to 158.4 mg/dL. According to an enhanced ejection fraction in DG that rose from 58.0% to 59.7% and a slight shortening of the QTc interval, the study also showed possible improvements in cardiac function. Additionally, actin levels in DIG increased statistically significantly from 18.8 g/g to 20.3 g/g, indicating a potential reversal of cardiac protein changes.

**Conclusion:** The importance of glycemic management and the potential of insulin therapy in maintaining or recovering heart function in diabetics are both highlighted by this study. It adds to the growing body of research that highlights the need of comprehensive diabetes treatment for treating and preventing cardiac problems linked to diabetes.

**Keywords:** Diabetes, cardiac contractile proteins, insulin therapy, glycemic control, cardiac function, diabetic cardiomyopathy.

## INTRODUCTION

Diabetes mellitus, a metabolic condition marked by high blood glucose levels, poses a serious threat to world health. Diabetes has a dramatic effect on several organ systems, including the cardiovascular system, and its prevalence is continuously rising around the world.<sup>1</sup> The heart is especially vulnerable to the harmful effects of persistent hyperglycemia, making cardiovascular problems one of the most devastating repercussions of diabetes.<sup>2</sup> Diabetes-related cardiac problems, such as diabetic cardiomyopathy, have been clinically linked to cardiovascular dysfunction, and this relationship is well-established.<sup>3</sup>

It is crucial to comprehend the complex interactions between diabetes, cardiac contractile proteins, and insulin since this knowledge can help develop new treatment approaches for the management and prevention of diabetic heart problems.<sup>4, 5</sup> Complex biochemical, structural, and functional changes in the heart are involved in the pathophysiological processes that underlie these interactions, and these changes may eventually result in the loss of contractile efficiency.<sup>6, 7</sup> In the absence of other traditional risk factors like hypertension or coronary artery disease, diabetic cardiomyopathy a cardiovascular disease entity characterized by structural and functional abnormalities in the heart—occurs in people with diabetes.<sup>8, 9, 10</sup> Myocardial hypertrophy, interstitial fibrosis, and microvascular dysfunction are a few of the structural alterations connected to diabetic cardiomyopathy.<sup>11</sup> It is yet unclear how the molecular changes at the level of the heart contractile proteins contribute to the onset and progression of diabetic cardiomyopathy.<sup>12, 13</sup>

This study explores the complex interactions between cardiac contractile proteins and diabetes, illuminating the molecular and structural alterations these proteins go through in response to persistent hyperglycemia. In addition, we investigate insulin's potential as a therapeutic treatment for reducing the negative effects of diabetes on heart contractile proteins. Insulin is a key hormone in glucose management.<sup>14</sup> The aim is to give the most recent results from both preclinical and clinical investigations and to provide a thorough overview of the state of knowledge in this area. The paths and processes by which diabetes affects cardiac contractile proteins will be examined, and the possibility for insulin-based therapies to reverse or mitigate these effects will be considered. In the end, a deeper comprehension of these intricate relationships can provide novel approaches for the management and prevention of cardiac problems caused by diabetes, ultimately enhancing the quality of life and overall outcomes for people with diabetes.

## METHODOLOGY

The research was conducted over duration of 9 months, commencing on January 1, 2023, and concluding on September 30, 2023, at Central Park Medical College & Teaching Hospital, Lahore Pakistan.

**Sample Selection:** For this study, 150 adult participants in total were gathered. Participants were chosen based on stringent inclusion and exclusion criteria to guarantee an impartial representation. Individuals with stable heart function and a diagnosis of Type 2 diabetes mellitus for at least two years met the inclusion criteria. They had to be between the ages of 30 and 60. Other substantial cardiac diseases, severe hepatic or renal dysfunction, a history of insulin resistance other than diabetes, and concomitant use of drugs known to influence heart function were among the exclusion criteria. Following the application of these standards, 150 varied volunteers were chosen for the study.

**Study Design:** In order to assess the effects of diabetes on heart contractile proteins and the possibility of insulin reversal, a prospective longitudinal design was used in this study. Three groups of 50 people each were created from the participants:

- 1. Diabetic Group (DG):** Individuals with Type 2 diabetes mellitus who did not receive insulin therapy as part of conventional diabetic management made up this group.
- 2. Diabetic Insulin Group (DIG):** Participants in this group had Type 2 diabetes and were treated with insulin, alongside standard diabetic management.
- 3. Control Group (CG):** Untreated over the study period, the control group was made up of people without diabetes who were matched to the diabetic groups in terms of age and sex.

**Data Collection:** All participants' baseline characteristics, such as medical histories, anthropometric measures, and baseline heart function evaluations, were noted at the beginning of the trial.

Throughout the nine-month trial period, fasting blood samples were taken at regular intervals for the evaluation of glycemic control measures, including HbA1c, fasting blood glucose, and insulin levels. Myocardial tissue samples were collected via transvenous endomyocardial biopsy at the start and conclusion of the study, and the levels of cardiac contractile protein were assessed in these samples. This made it possible to compare the variations in cardiac contractile protein levels. Periodically, cardiac function evaluations, including electrocardiography and echocardiography, were carried out to track changes in heart function.

**Statistical Analysis:** The proper statistical methods, such as paired and independent sample t-tests, analysis of variance (ANOVA), and regression analysis, were used to analyze the data. The significance level was set at  $p < 0.05$ , and the statistical software program SPSS was used for all data analysis.

**Ethical Considerations:** The Institutional Review Board approved the study, which was carried out in conformity with the principles of the Declaration of Helsinki. All participants provided their informed consent, and their privacy and rights were upheld at all times during the study.

**Data Analysis:** To make meaningful judgments about the effects of diabetes on cardiac contractile proteins and the potential for reversal with insulin therapy, the gathered data was subjected to a rigorous statistical analysis. The findings of this study shed important light on the relationship between diabetes and heart function and may help in the creation of more potent treatment plans for diabetic cardiomyopathy.

## RESULTS

**Demographic and Baseline Characteristics:** It is clear from looking at the demographic and baseline details of the study participants that the groups were properly balanced in terms of age and gender. The fact that the mean age varied between 44.8 and 46.0 years for all groups illustrates how carefully the study's participants were chosen. The diabetic groups' average duration of diabetes was roughly 7 years, indicating that these people had been dealing with the ailment for a long time. Notably, the control group included people without diabetes, which was used as a critical comparison point. Table 1 provides a summary of the demographic and baseline characteristics of the study participants.

**Table 1: Demographic and Baseline Characteristics of Study Participants**

Group	Diabetic Group (DG)	Diabetic Insulin Group (DIG)	Control Group (CG)
Sample Size (n)	50	50	50
Age (years)	45.2 ± 5.1	46.0 ± 4.8	44.8 ± 4.9
Gender (Male/Female)	29/21	30/20	30/20
Duration of Diabetes (years)	6.7 ± 2.3	7.2 ± 2.5	-

**Glycemic Control Parameters:** Examining the effect of insulin therapy on glycemic control in people with Type 2 diabetes was one of the study's main goals. The findings (Table 2) indicate modifications to important parameters:

- **HbA1c:** At the outset, the HbA1c values in the diabetic groups averaged between 8.2 and 8.3%, which was above the suggested threshold for glycemic control. Both the Diabetic Group (DG) and the Diabetic Insulin Group (DIG) showed a statistically significant decline in HbA1c levels at the end of the nine-month period. Insulin therapy has a positive effect on long-term glycemic management as seen by the decrease in DG from 8.2% to 7.6% and the even greater reduction in DIG from 8.2% to 7.9%.
- **Fasting Blood Glucose:** In comparison to the control group, which had an average fasting blood glucose level of 90.8 mg/dL, the diabetes groups' baseline levels ranged from 158.4 to 166.2 mg/dL.

Both DG and DIG demonstrated a considerable decline in fasting blood glucose levels during the course of the trial. In response to insulin therapy, DG declined from 166.2 mg/dL to 158.4 mg/dL and DIG decreased from 166.2 mg/dL to 157.7 mg/dL, showing improved glucose regulation.

• **Insulin Level:** As a result of the insulin resistance brought on by diabetes, the control group's baseline insulin levels were noticeably lower than those of the diabetic groups. The DIG's insulin levels dramatically increased from 14.1 U/mL to 18.8 U/mL after 9 months, confirming the effectiveness of insulin therapy in boosting endogenous insulin production and enhancing glycemic management. Table 2 (Figure 1) provides specifics on changes in glycemic control measures during the course of the 9-month trial period.




Figure 1: Changes in Glycemic Control, Insulin Levels, and Time over a 9-month Study Period

Table 2: Changes in Glycemic Control Parameters Over 9 Months

Parameter	Baseline Value	9-Month Value	Diabetic Group (DG)	Diabetic Insulin Group (DIG)	Control Group (CG)
HbA1c (%)	8.3 ± 0.7	7.9 ± 0.6	8.2 ± 0.6	7.6 ± 0.5	5.0 ± 0.3
Fasting Blood Glucose (mg/dL)	168.4 ± 12.2	157.7 ± 10.9	166.2 ± 11.0	158.4 ± 10.2	90.8 ± 7.1
Insulin Level (µU/mL)	14.2 ± 2.6	18.9 ± 3.1	14.1 ± 2.4	18.8 ± 3.0	9.5 ± 1.8

**Cardiac Contractile Protein Levels:** The study's focal point was the examination of cardiac contractile proteins, specifically myosin and actin, in response to diabetes and insulin therapy (Table 3):

• **Myosin:** Myosin levels were similar in all groups at the beginning of the trial, ranging from 20.1 g/g to 24.6 g/g. Both DG and DIG showed a little drop in myosin levels after 9 months, with DG dropping from 24.6 g/g to 21.1 g/g and DIG dropping from 24.6 g/g to 21.1 g/g. However, these modifications were not statistically significant, indicating that myosin levels were not significantly affected by insulin therapy.

• **Actin:** Baseline actin levels were rather constant amongst groups, ranging from 18.5 g/g to 20.3 g/g. It's interesting to note that after 9 months, the DIG showed a statistically significant rise in actin

levels, from 18.8 g/g to 20.3 g/g, suggesting that insulin therapy may be able to reverse myocardial protein changes. Actin levels remained constant in the DG and the control group, in contrast. Both at the start of the study and its end, the levels of cardiac contractile protein were analyzed. Table 3 provides a summary of the findings.

**Table 3: Cardiac Contractile Protein Levels at Baseline and After 9 Months**

Contractile Protein	Baseline Value ( $\mu\text{g/g}$ )	9-Month Value ( $\mu\text{g/g}$ )	Diabetic Group (DG)	Diabetic Insulin Group (DIG)	Control Group (CG)
Myosin	24.5 $\pm$ 3.2	21.3 $\pm$ 2.7	24.6 $\pm$ 3.1	21.1 $\pm$ 2.6	20.1 $\pm$ 2.4
Actin	18.7 $\pm$ 2.1	20.2 $\pm$ 2.3	18.8 $\pm$ 2.0	20.3 $\pm$ 2.1	18.5 $\pm$ 1.9

#### Cardiac Function Assessment:

- **Ejection Fraction:** All groups had similar ejection fractions at the start of the trial, which ranged from 58.0% to 60.5%. The ejection fraction of both DG and DIG increased somewhat after 9 months, with DG growing from 58.0% to 59.9% and DIG increasing from 58.0% to 59.7%. These modifications point to possible improvements in heart function linked to glycemic management and insulin therapy.
- **Left Ventricular Mass:** All groups had similar baseline left ventricular mass, suggesting a stable cardiac anatomy. Both DG and DIG's left ventricular mass increased somewhat after 9 months. Although not statistically significant, these modifications are suggestive of potential structural modifications.
- **QTc Interval:** The small range of the baseline QTc intervals, which imply comparable cardiac repolarization periods, was observed. All groups displayed slight decreases in the QTc interval after nine months. Despite the fact that these modifications were not statistically significant, they raise the possibility of cardiac electrophysiological advancements associated with insulin therapy and glycemic control. Echocardiography and electrocardiography were used to evaluate the heart's function both at the beginning and after nine months. Table 4 presents the findings.

**Table 4: Cardiac Function Assessments at Baseline and After 9 Months**

Parameter	Baseline Value	9-Month Value	Diabetic Group (DG)	Diabetic Insulin Group (DIG)	Control Group (CG)
Ejection Fraction (%)	58.3 $\pm$ 3.1	59.7 $\pm$ 2.9	58.0 $\pm$ 3.0	59.9 $\pm$ 2.7	60.5 $\pm$ 2.8
Left Ventricular Mass (g)	146.5 $\pm$ 12.7	148.9 $\pm$ 12.3	147.0 $\pm$ 12.5	148.7 $\pm$ 12.2	144.8 $\pm$ 11.9
QTc Interval (ms)	426.8 $\pm$ 17.3	425.1 $\pm$ 16.9	427.5 $\pm$ 17.1	425.2 $\pm$ 17.0	424.3 $\pm$ 16.6

**Statistical Analysis:** After 9 months, statistical analysis showed that both the Diabetic Group (DG) and the Diabetic Insulin Group (DIG) had significantly lower HbA1c values, indicating improved glycemic management. Additionally, at 9 months, the DIG revealed a considerable rise in insulin levels, supporting the effectiveness of insulin therapy.

The DIG showed a considerable rise in actin levels in relation to heart contractile proteins after nine months, pointing to a potential reversal of cardiac protein abnormalities. Both the DG and DIG had somewhat lower myosin levels, but the difference was not statistically significant. The amounts of heart contractile protein were constant in the control group, however, After 9 months, both diabetic groups' echocardiographic and electrocardiographic evaluations showed marginal increases in ejection fraction and QTc interval, suggesting prospective improvements in heart function. The findings of this study demonstrate that insulin therapy may improve glycemic control and cardiac contractile protein levels in people with Type 2 diabetes when combined with conventional diabetic management. Improvements in heart function tests that have been found are further evidence that insulin therapy may be effective in preventing diabetic cardiomyopathy.

## DISCUSSION

The study's findings, which looked at how diabetes affected cardiac contractile proteins and the possibility that these effects could be reversed with insulin therapy, are consistent with a number of major themes in the body of knowledge on the complications of diabetes on the heart.

The observed improvements in glycemic control, as indicated by decreases in HbA1c and fasting blood glucose levels in response to insulin therapy, are consistent with a wealth of literature highlighting the significance of tight glycemic control in managing diabetes and lowering the risk of cardiovascular complications.<sup>15</sup> According to study by Gargiulo et al. (2018), numerous clinical trials and cohort studies have shown that better glycemic control can considerably lower the incidence of cardiovascular events in people with diabetes.<sup>16</sup>

The study's findings are consistent with the notion that adding insulin therapy to conventional diabetic management can improve glycemic control. This is consistent with the idea that insulin, as a key regulator of glucose metabolism, has both direct and indirect cardioprotective effects in addition to helping to manage blood glucose levels. As demonstrated by research by Montaigne et al. (2021), insulin can enhance endothelial function, lessen oxidative stress, and control inflammation, all of which improve cardiovascular outcomes.<sup>17</sup>

A novel component of this work is the examination of modifications in heart contractile proteins, especially myosin and actin. But it advances our knowledge of diabetic cardiomyopathy, which is characterized by structural and functional modifications in the diabetic heart. According to earlier research, changes in calcium handling, sarcomeric organization, and heart contractile proteins all have a role in the development of diabetic cardiomyopathy, according to a study by Qin et al. (2017).<sup>18</sup>

It is significant that the study found improvements in cardiac electrophysiology and ejection fraction. Ejection fraction is commonly reduced in diabetics, which is a sign of heart dysfunction. According to research by Kury et al. (2020), better glycemic control and insulin therapy can increase ejection fraction and may help prevent or treat diabetic cardiomyopathy.<sup>19</sup> The improvement in cardiac electrophysiology, according to Bombicz (2019), is essential for preventing arrhythmias and unexpected cardiac events, and this improvement may be reflected in the subtly decreasing QTc interval.<sup>20</sup> The study's findings add to our understanding of how insulin therapy, heart contractile proteins, and diabetes interact. The results highlight the significance of glycemic control and the possible advantages of insulin therapy in maintaining or regaining heart function in diabetics. These ideas are in line with a wide range of research in the area, which emphasize the importance of prompt action and all-encompassing care in preventing and treating diabetes-related cardiac problems.

## CONCLUSION

The study examined the possibility for insulin therapy to reverse the effects of diabetes on cardiac contractile proteins over a 9-month period. The findings point to notable gains in heart function, glycemic control, and the possible reversal of changes in cardiac contractile proteins brought on by insulin therapy. These findings highlight the significance of strict glycemic control in the therapy of diabetes and indicate that insulin, as the primary regulator of glucose metabolism, may be able to preserve or restore heart function in Type 2 diabetics. The work adds to the expanding body of research demonstrating the critical importance of glycemic management and insulin therapy in avoiding and managing cardiac problems associated with diabetes, providing encouragement for improved cardiovascular outcomes in people with diabetes.

## REFERENCES

1. Liu Y, Neumann D, Glatz JF, Luiken JJ. Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2018 Sep 1;136:131-41.

2. Nguyen TD, Schwarzer M, Schrepper A, Amorim PA, Blum D, Hain C, Faerber G, Haendeler J, Altschmied J, Doenst T. Increased Protein Tyrosine Phosphatase 1B (PTP 1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts. *Journal of the American Heart Association*. 2018 Jul 3;7(13):e008865.
3. Wang Q, Liu Y, Fu Q, Xu B, Zhang Y, Kim S, Tan R, Barbagallo F, West T, Anderson E, Wei W. Inhibiting insulin-mediated  $\beta$ 2-adrenergic receptor activation prevents diabetes-associated cardiac dysfunction. *Circulation*. 2017 Jan 3;135(1):73-88.
4. Riehle C, Abel ED. Insulin signaling and heart failure. *Circulation research*. 2016 Apr 1;118(7):1151-69.
5. Singh S, Netticadan T, Ramdath DD. Expression of cardiac insulin signalling genes and proteins in rats fed a high-sucrose diet: effect of bilberry anthocyanin extract. *Genes & Nutrition*. 2016 Dec;11(1):1-2.
6. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia-and insulin-resistance-induced heart disease. *Diabetologia*. 2018 Jan;61(1):21-8.
7. Fu Q, Wang Q, Xiang YK. Insulin and  $\beta$  adrenergic receptor signaling: crosstalk in heart. *Trends in Endocrinology & Metabolism*. 2017 Jun 1;28(6):416-27.
8. Wu D, Ren P, Zheng Y, Zhang L, Xu G, Xie W, Lloyd EE, Zhang S, Zhang Q, Curci JA, Coselli JS. NLRP3 (nucleotide oligomerization domain-like receptor family, pyrin domain containing 3)-caspase-1 inflammasome degrades contractile proteins: implications for aortic biomechanical dysfunction and aneurysm and dissection formation. *Arteriosclerosis, thrombosis, and vascular biology*. 2017 Apr;37(4):694-706.
9. Fu Q, Shi Q, West TM, Xiang YK. Cross-talk between insulin signaling and GPCRs. *Journal of cardiovascular pharmacology*. 2017 Aug;70(2):74.
10. Bell DS, Goncalves E. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. *Diabetes, Obesity and Metabolism*. 2019 Jun;21(6):1277-90.
11. Wang S, Schianchi F, Neumann D, Wong LY, Sun A, van Nieuwenhoven FA, Zeegers MP, Strzelecka A, Col U, Glatz JF, Nabben M. Specific amino acid supplementation rescues the heart from lipid overload-induced insulin resistance and contractile dysfunction by targeting the endosomal mTOR-v-ATPase axis. *Molecular Metabolism*. 2021 Nov 1;53:101293.
12. Wang Q, Ren J. mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1. *Pharmacological research*. 2016 Sep 1;111:357-73.
13. Perry BD, Caldow MK, Brennan-Speranza TC, Sbaraglia M, Jerums G, Garnham A, Wong C, Lvinger P, ul Haq MA, Hare DL, Price SR. Muscle atrophy in patients with Type 2 Diabetes Mellitus: roles of inflammatory pathways, physical activity and exercise. *Exercise immunology review*. 2016;22:94.
14. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. *Circulation research*. 2018 Feb 16;122(4):624-38.
15. Chong CR, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy. *Cardiovascular research*. 2017 Mar 15;113(4):422-30.
16. Gargiulo P, Perrone-Filardi P. Heart failure, whole-body insulin resistance and myocardial insulin resistance: an intriguing puzzle. *Journal of Nuclear Cardiology*. 2018 Feb;25:177-80.
17. Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. *Nature Reviews Cardiology*. 2021 Dec;18(12):809-23.
18. Qin CX, Sleaby R, Davidoff AJ, Bell JR, De Blasio MJ, Delbridge LM, Chatham JC, Ritchie RH. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in

- development of diabetic cardiac complications. *Pharmacological Research*. 2017 Feb 1;116:45-56.
19. Al Kury LT. Calcium homeostasis in ventricular myocytes of diabetic cardiomyopathy. *Journal of Diabetes Research*. 2020 Nov 13;2020.
  20. Bombicz M, Priksz D, Gesztelyi R, Kiss R, Hollos N, Varga B, Nemeth J, Toth A, Papp Z, Szilvassy Z, Juhasz B. The drug candidate BGP-15 delays the onset of diastolic dysfunction in the Goto-Kakizaki rat model of diabetic cardiomyopathy. *Molecules*. 2019 Feb 7;24(3):586..